BMS-919373

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H20N6O2S
Molecular Weight	468.53
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NS(=O)(=O)C1=CC(=CN=C1)C2=NC3=CC=CC(C4=CC=CC=C4)=C3C(NCC5=CC=CC=N5)=N2

InChI

InChIKey=XGKULQQVQWCASY-UHFFFAOYSA-N

InChI=1S/C25H20N6O2S/c26-34(32,33)20-13-18(14-27-16-20)24-30-22-11-6-10-21(17-7-2-1-3-8-17)23(22)25(31-24)29-15-19-9-4-5-12-28-19/h1-14,16H,15H2,(H2,26,32,33)(H,29,30,31)

HIDE SMILES / InChI

Molecular Formula	C25H20N6O2S
Molecular Weight	468.53
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Bristol-Myers Squibb developed BMS-919373, a selective IKur inhibitor for use in atrial fibrillation, acute coronary syndromes, and paroxysmal atrial fibrillation. IKur is a repolarizing K+ current encoded by the KCNA5 gene and is expressed predominantly in the atrium of human. IKur is a potential atrial-selective target for the treatment of atrial fibrillation. BMS-919373 participated in phase II clinical trials to evaluate the effect on atrial fibrillation burden in patients with paroxysmal atrial fibrillation. In addition, in phase I clinical trials for patients with acute coronary syndromes. However, further, developments have been discontinued.

Originator

Approval Year

PubMed

PubMed

Show entries

Title	Date	PubMed
Utilizing Native Directing Groups: Synthesis of a Selective I(Kur) Inhibitor, BMS-919373, via a Regioselective C-H Arylation.	2019 Apr 19	30395712

Showing 1 to 1 of 1 entries

Previous1Next

Sample Use Guides

In Vivo Use Guide

BMS-919373 3 mg tablets orally once daily for approximately 28 days.

Route of Administration: Oral

Substance Class	Chemical
Record UNII	NGB50MQK8N
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

BMS-919373

Common Name

English

3-PYRIDINESULFONAMIDE, 5-(5-PHENYL-4-((2-PYRIDINYLMETHYL)AMINO)-2-QUINAZOLINYL)-

Systematic Name

English

5-(5-PHENYL-4-(((PYRIDIN-2-YL)METHYL)AMINO)QUINAZOLIN-2-YL)PYRIDINE-3-SULFONAMIDE

Systematic Name

English

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

51030730

PRIMARY

FDA UNII

NGB50MQK8N

PRIMARY

MANUFACTURER PRODUCT INFORMATION

BMS-919373

PRIMARY

MedKoo CAT NO: 522698, CAS NO: 1272353-82-8Description: BMS-919373 is a Potassium channel Kv1.5 (KCNA5) inhibitor for use in atrial fibrillation and acute coronary syndromes. Phase II development is underway in the US and Canada for paroxysmal atrial fibrillation. (last updated: 4/6/2016).Synonym: BMS-919373, BMS 919373, BMS919373.

DRUG BANK

DB15047

PRIMARY

CAS

1272353-82-8

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					NGB50MQK8N

BMS-919373

ACTIVE MOIETY

Comments:

Drugs: BMS-919373(Primary), Sotalol; Indication: Atrial fibrillation; Focus: Therapeutic Use; Sponsor: Bristol-Myers Squibb; Most Recent Events: 11 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov record., 11 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov record., 06 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.


					NGB50MQK8N

BMS-919373

ACTIVE MOIETY

Comments:

Official Title: A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker Purpose: To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.

Showing 1 to 2 of 2 entries

Previous1Next